ABSTRACT
Trastuzumab, a monoclonal antibody, is effective in HER2 positive breast cancer patients but cardiotoxicity is problem. The aim of this study was to clarify the possible effects of Valsartan on echocardiographic ejection fraction and cardiac biomarkers (serum brain natriuretic peptide and malondialdehyde) in trastuzumab treated females with breast cancer over expressing HER2 receptor. Twenty six female patients with new diagnosis of HER2 positive breast cancer were randomly assigned to 8 cycles trastuzumab treatment (group I, no= 13) or trastuzumab plus Valsartan 40 mg (group II, no= 13). Echocardiography ejection fraction was analyzed at base line, 4th and 8th cycles in both groups. Serum malondialdehyde and brain natriuretic peptide were analyzed at base line, 2nd, 4th, 6th and 8th cycles in both groups. Treatment with trastuzumab caused significant decrease in echocardiographic ejection fraction at 8th cycle treatment in comparison to baseline readings (P < 0.05). A significant increase in echocardiographic ejection fraction was obtained by group II (trastuzumab plus Valsartan group) in comparison with that of trastuzumab therapy group (P < 0.05). Regarding
serum brain natriuretic peptide and Malondialdehyde, trastuzumab therapy caused significant increase in both these markers
compared with the baseline readings (P < 0.05).Combined trastuzumab plus Valsartan caused significant decrease in serum brain natriuretic peptide and Malondialdehyde compared with that of trastuzumab therapy group (P < 0.05). In trastuzumab treated patients, Valsartan causes significant increase in ejection fraction with significant decrease in both serum brain natriuretic peptide and malondialdehyde.
(FULL ARTICLE LINK) Read more ...
30-11-2014
|
|
|
